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In September 2003, our groups published a joint paper 
[1] in Journal of Biology (now BMC Biology) that 
identified the long-sought and elusive upstream kinase 
acting on AMP-activated protein kinase (AMPK) as a 
complex containing LKB1, a known tumor suppressor. 
Similar findings were reported at about the same time by 
David Carling and Marian Carlson [2] and by Reuben 
Shaw and Lew Cantley [3]; at the time of writing these 
three papers have received between them a total of over 
2,000 citations. These findings provided a direct link 
between a protein kinase, AMPK, which at the time was 
mainly associated with regulation of metabolism, and 
another protein kinase, LKB1, which was known from 
genetic studies to be a tumor suppressor. While the idea 
that cancer is in part a metabolic disorder (first suggested 
by Warburg in the 1920s [4]) is well recognized today [5], 
this was not the case in 2003, and our paper perhaps 
contributed towards its renaissance. The aim of this short 
review is to recall how we made the original finding, and 
to discuss some of the directions that these findings have 
taken the field in the ensuing ten years.
AMPK as an energy sensor and metabolic switch
AMPK was discovered as a protein kinase activity that 
phosphorylated and inactivated two key enzymes of fatty 
acid and sterol biosynthesis: acetyl-CoA carboxylase 
(ACC) and 3-hydroxy-3-methylglutaryl-CoA reductase 
(HMGR). The ACC kinase activity was reported to be 
activated by 5’-AMP [6], and the HMGR kinase activity 
by reversible phosphorylation [7], but for many years the 
two activities were thought to be due to distinct enzymes. 
However, in 1987 the DGH laboratory showed that both 
were functions of a single protein kinase [8], which we 
renamed AMPK after its allosteric activator, 5’-AMP [9]. 
It was subsequently found that AMPK regulated not only 
lipid biosynthesis, but also many other metabolic 
pathways, both by direct phosphorylation of metabolic 
enzymes, and through longer-term effects mediated by 
phosphorylation of transcription factors and co-
activators. In general, AMPK switches off anabolic 
pathways that consume ATP and NADPH, while 
switching on catabolic pathways that generate ATP 
(Figure 1). Findings that AMPK is activated in skeletal 
muscle during exercise [10] and that it increases muscle 
glucose uptake and fatty acid oxidation [11] led to the 
suggestion that AMPK-activating drugs might be useful 
for treating type 2 diabetes [12]. Indeed, it turned out 
that AMPK is activated by metformin, a drug that had at 
that time been used to treat type 2 diabetes for over 40 
years, [13], and by phenformin [1], a closely related drug 
that had been withdrawn for treatment of diabetes due to 
side effects of lactic acidosis.
Metformin and phenformin are biguanides that inhibit 
mitochondrial function and so deplete ATP by inhibiting 
its production [14]. AMPK is activated by any metabolic 
stress that depletes ATP, either by inhibiting its 
production (as do hypoxia, glucose deprivation, and 
treatment with biguanides) or by accelerating its 
consumption (as does muscle contraction [10]). By 
switching off anabolism and other ATP-consuming 
processes and switching on alternative ATP-producing 
catabolic pathways, AMPK acts to restore cellular energy 
homeostasis. When ATP is consumed, both ADP and 
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The identification of a complex containing the tumor 
suppressor LKB1 as the critical upstream kinase 
required for the activation of AMP-activated protein 
kinase (AMPK) by metabolic stress was reported in 
an article in Journal of Biology in 2003. This finding 
represented the first clear link between AMPK and 
cancer. Here we briefly discuss how this discovery 
came about, and describe some of the insights, 
especially into the role of AMPK in cancer, that have 
followed from it.
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10th anniversary
AMP increase, and it has recently become clear that both 
of the latter are activators of AMPK. ATP competes with 
AMP and ADP for binding to regulatory sites on the 
enzyme, thus preventing activation; activation of AMPK 
therefore depends on the ratios of ATP:ADP and 
AMP:ATP, and in this way the enzyme acts as a sensor of 
the metabolic state of the cell.
AMPK has two regulatory subunits, β and γ, along with 
its catalytic α subunit (Figure 2). Like most kinases, it is 
activated by phosphorylation of a residue within the 
activation loop of the kinase domain (Thr172). The γ 
subunit contains four tandem sequence repeats known as 
CBS repeats, which are arranged in a pseudo-
symmetrical manner to yield four potential adenine 
nucleotide-binding clefts. One of these (site 2) appears 
always to be unoccupied, one (site 4) appears to have 
permanently bound AMP, while the remaining two 
(1 and 3) bind AMP, ADP or ATP in competition 
[15,16]. In an unstressed cell where ATP:ADP ratios are 
high, sites 1 and 3 are probably largely occupied by ATP, 
but when a cell undergoes metabolic stress the 
concentrations of ADP and AMP increase relative to 
ATP, and they will progressively replace ATP at sites 1 
and 3. Thr172 appears to be phosphorylated constantly 
by the upstream kinase, but under unstressed conditions 
it is immediately dephosphorylated, so that the net 
phosphorylation state remains close to zero. However, 
binding of ADP and/or AMP to the γ subunit both 
promotes phosphorylation and inhibits dephosphoryla-
tion of Thr172, causing a sensitive switch to the active, 
phosphorylated form. In addition, binding of AMP (but 
not ADP) causes a further allosteric activation of the 
phosphorylated kinase; this additional mechanism may 
further amplify the response in a severely stressed cell in 
which AMP levels are high.
This leaves open the question of the activating kinase 
that phosphorylates Thr172. It had been known since 
studies of ‘HMGR kinase’ in 1978 [7] that AMPK was 
activated by a distinct upstream kinase, but its identity 
had remained enigmatic.
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Figure 1. Summary of a selection of target proteins and metabolic pathways regulated by AMPK. Anabolic pathways switched off by 
AMPK are shown in the top half of the ‘wheel’ and catabolic pathways switched on by AMPK in the bottom half. Where a protein target for AMPK 
responsible for the effect is known, it is shown in the inner wheel; a question mark indicates that it is not yet certain that the protein is directly 
phosphorylated. For original references see [54]. Key to acronyms: ACC1/ACC2, acetyl-CoA carboxylases-1/-2; HMGR, HMG-CoA reductase; SREBP1c, 
sterol response element binding protein-1c; CHREBP, carbohydrate response element binding protein; TIF-1A, transcription initiation factor-1A; 
mTORC1, mechanistic target-of-rapamycin complex-1; PFKFB2/3, 6-phosphofructo-2-kinase, cardiac and inducible isoforms; TBC1D1, TBC1 domain 
protein-1; SIRT1, sirtuin-1; PGC-1α, PPAR-γ coactivator-1α; ULK1, Unc51-like kinase-1.
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Discovery of the link between LKB1 and AMPK
Although by 1996 the DGH laboratory had partially 
purified an upstream kinase from rat liver that 
phosphorylated r172 [17], we had been unable to 
identify it. e breakthrough came when we switched to 
the yeast Saccharomyces cerevisiae, which contains a 
protein kinase (the SNF1 complex) that is a clear 
orthologue of AMPK [18,19]. e S. cerevisiae genome 
sequence had just been completed, and we screened a 
yeast kinome expression library for kinases that activated 
mammalian AMPK. is yielded Elm1 as a single hit, 
although, frustratingly, knocking out the ELM1 gene did 
not produce the same phenotype as knocking out SNF1. 
However, Martin Schmidt’s group had just shown that a 
closely related kinase, Pak1 (now called Sak1) could also 
phosphorylate and activate the SNF1 complex [20], and 
working with him we observed the expected phenotype 
by making a triple knockout not only of Elm1 and Sak1 
but also of Tos3, a third closely related kinase [21]. e 
Carling and Carlson groups simultaneously identified the 
same three upstream kinases [22].
Although there were no clear orthologues of Elm1, 
Sak1 or Tos3 in mammals, the human kinase with closest 
sequence similarity (at least within the kinase domain) 
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Figure 2. Structure graphic of AMPK. The α subunit is in red, the β subunit in green, and the four CBS motifs of the γ subunit in various shades 
of blue, magenta and cyan. For this structure, an AMPK complex phosphorylated on Thr172, lacking most of the β subunit and also a flexible loop 
from the α subunit, was crystallized in the presence of AMP and the kinase inhibitor staurosporine. For clarity, only the AMP in site 3 is shown, but 
the approximate location of binding clefts 1, 2 and 4 are also shown; in this view, sites 1 and 4 are at the back of the γ subunit and sites 2 and 3 at 
the front. The carboxy-terminal domain of the β subunit forms the core of the complex, bridging the carboxy-terminal domain of the α subunit 
and the γ subunit. Note the extended α subunit linker peptide between the kinase domain and carboxy-terminal domain, with its ‘α hook’ region 
contacting AMP in site 3. AID: α subunit autoinhibitory domain (this domain is believed to hold the catalytic domain in an inactive conformation in 
the absence of the regulatory domains). Drawn using MacPyMOL with Protein Database Entry 2Y94 [15].
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was LKB1 (liver kinase B1), which had been identified 
five years earlier as a tumor suppressor mutated in an 
inherited cancer susceptibility called Peutz-Jeghers 
syndrome [23,24]. The DRA laboratory had started to 
study LKB1 at that time, and had made the key 
observation that the enzyme was only active as a complex 
with two accessory subunits called STRAD and MO25 
[25,26]. Working together, we were quickly able to 
demonstrate (using antibodies that DRA had generated) 
that the upstream kinase that the DGH group had been 
trying to purify from rat liver was indeed an LKB1-
STRAD-MO25 complex. We also showed that activation 
of AMPK by metabolic stress in LKB1-null cells was 
defective, but could be rescued by re-expression of LKB1. 
These findings formed the basis of our paper in Journal of 
Biology [1]. The LKB1 complex was not itself regulated by 
AMP, with the effects of AMP or ADP on Thr172 
phosphorylation being due instead, as described above, 
to binding of the nucleotides to the substrate, AMPK, 
causing conformational changes that promote 
phosphorylation and inhibit dephosphorylation [15,27-
29] (Figure 3).
The immediate aftermath (1): more kinases 
downstream of LKB1
While it was clear at that time that most kinases require 
phosphorylation in the activation loop to become active, 
it was also self-evident that there could not be a specific 
upstream kinase for every downstream kinase. The DRA 
group had previously identified PDK1 as the upstream 
kinase for PKB/Akt [30], and shown that it was also 
upstream of several other members of the AGC kinase 
family, introducing the concept of ‘master upstream 
kinases’ [31]. The two catalytic subunit isoforms of 
AMPK (α1 and α2) lie on a small sub-branch of the 
CaMK kinase family [32] that also contains 12 other 
kinases now referred to as the AMPK-related kinases or 
ARKs. Since the sequence around the site equivalent to 
Thr172 is highly conserved between AMPK and the 
ARKs, it seemed possible that LKB1 was a master kinase 
upstream of the whole subfamily, and this was soon 
shown to be the case [33,34] (Figure 4). Indeed, LKB1 
activates all 12 ARKs by phosphorylating the residue 
equivalent to Thr172, and their activity is greatly 
diminished in LKB1-deficient cells.
Although the roles of the ARKs are poorly understood 
by comparison with those of AMPK, initial studies 
suggest that they play critical roles in regulating aspects 
of cell polarity (MARK, BRSK/SAD), cell proliferation 
(NUAKs) and CREB-regulated gene transcription (SIKs). 
The catalytic subunits of the ARKs do not interact with 
the γ subunits that provide the AMP/ADP sensing 
function of the AMPK complex [35], so they are not 
regulated by energy stress like AMPK, and indeed it is 
not yet understood how their activity and 
phosphorylation is regulated at the molecular level. As 
discussed below, however, their existence complicates the 
interpretation of the metabolic and tumor suppressor 
effect of LKB1, in particular in the case of the NUAKs, 
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Figure 3. Regulation of AMPK. AMPK can be activated by increases 
in cellular AMP:ATP or ADP:ATP ratio, or Ca2+ concentration. AMPK 
is activated >100-fold on conversion from a dephosphorylated 
form (AMPK) to a form phosphorylated at Thr172 (AMPK-P) 
catalyzed by at least two upstream kinases: LKB1, which appears 
to be constitutively active, and CaMKKβ, which is only active when 
intracellular Ca2+ increases. Increases in AMP or ADP activate AMPK 
by three mechanisms: (1) binding of AMP or ADP to AMPK, causing a 
conformational change that promotes phosphorylation by upstream 
kinases (usually this will be LKB1, unless [Ca2+] is elevated); (2) binding 
of AMP or ADP, causing a conformational change that inhibits 
dephosphorylation by protein phosphatases; (3) binding of AMP (and 
not ADP), causing allosteric activation of AMPK-P. All three effects are 
antagonized by ATP, allowing AMPK to act as an energy sensor.
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Figure 4. Members of the AMPK and AMPK-related kinase (ARK) 
family. All the kinases named in the figure are phosphorylated and 
activated by LKB1, although what regulates this phosphorylation is 
known only for AMPK. Alternative names are shown, where applicable.
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which appear to be involved in regulation of cell 
proliferation, and the SIKs, involved in the regulation of 
gluconeogenesis.
The immediate aftermath (2): more kinases 
upstream of AMPK
Our 2003 paper [1] showed that although genetic loss of 
LKB1 in mammalian cells greatly reduces 
phosphorylation of AMPK on Thr172, it does not 
eliminate it entirely, suggesting that other kinases must 
also phosphorylate the site. The DGH group had reported 
in 1995 that calmodulin-dependent kinase kinases 
(CaMKKs) could activate AMPK [27], although it was 
not clear at the time that this was physiologically 
relevant. However, DGH and others soon reported that 
CaMKKs (especially the CaMKKβ isoform) did indeed 
provide an alternative Ca2+-stimulated pathway by which 
AMPK could be activated in intact cells in the absence of 
LKB1 [36-38]. This pathway accounts for AMPK 
activation in neurones exposed to membrane 
depolarization [36], in T cells activated via the antigen 
receptor [39], and in cells treated with ligands for G 
protein-coupled receptors that trigger intracellular 
release of inositol trisphosphate and hence Ca2+. The 
latter include endothelial cells treated with thrombin 
[40], and hypothalamic neurones involved in appetite 
control treated with the ‘hunger hormone’ ghrelin 
[41,42]. Interestingly, despite the very close sequence 
similarities within the activation loops of AMPK and the 
ARKs, none of the ARKs appear to be phosphorylated 
and activated by CaMKKβ [43].
New findings arising from genetic ablation of LKB1
Null mutations of either LKB1 or AMPK are embryonic 
lethal in mice, which means that conditional knockouts 
are necessary to study their function in vivo. This is, 
however, complicated in the case of AMPK by the 
existence of two or three functionally redundant isoforms 
of each of the three subunits, so that genes encoding all 
isoforms of one subunit must be knocked out to produce 
a phenotype. The identification of LKB1 as the upstream 
kinase activating AMPK simplified the investigation of 
AMPK function in vivo, because LKB1 is encoded by a 
single gene. It allowed the demonstration, for example, 
that mice with a muscle-specific knockout of LKB1, in 
which AMPK was no longer activated by contraction, 
failed to display the normal increase in muscle glucose 
uptake in response to contraction [44]. The convenience 
of having to knock out only a single gene is 
counterbalanced, however, by the status of LKB1 as a 
master upstream kinase that also acts upstream of the 
ARKs: thus, a phenotype caused by a tissue-specific 
LKB1 knockout cannot simply be ascribed to loss of 
AMPK activation without additional evidence. In the 
case of the muscle-specific LKB1 knockout, such 
evidence has been provided by a later study showing that 
skeletal muscle in which both AMPK-β subunits are 
knocked out to ablate AMPK activity have a rather 
similar phenotype [45]. By contrast, distinct effects of 
knocking out LKB1 and AMPK can be seen in the case of 
the liver, in which loss of LKB1 causes marked 
hyperglycemia, whereas mice with liver-specific loss of 
both AMPK catalytic subunits are normoglycemic. The 
more severe phenotype caused by ablation of LKB1 
rather than AMPK in the liver may be due to reduced 
activity of SIK1, which as mentioned earlier regulates 
expression of gluconeogenic genes [46].
The role of AMPK in cancer
As pointed out in an accompanying mini-review at the 
time [47], perhaps the biggest impact of our paper and 
the others linking LKB1 and AMPK [1-3] came from the 
link they established between a tumor suppressor (LKB1) 
with roles in cancer, and a protein kinase (AMPK) that 
had previously been regarded as a regulator of 
metabolism, with clinical implications in diabetes but not 
in cancer. While such a link had been suggested 
previously by pioneering work from the Esumi laboratory 
[48,49], the three simultaneous reports that LKB1 acted 
upstream of AMPK brought it into sharper focus. A key 
question was whether the tumor suppressor functions of 
LKB1 were mediated by AMPK, or by one or more of the 
ARKs, or both. This has still not been completely 
resolved, although there are good reasons for expecting 
that AMPK may mediate some of the tumor suppressor 
functions of LKB1. Indeed, a tumor suppressor function 
for AMPK is supported by a recent paper reporting that a 
whole-body knockout of AMPK-α1, which is the only 
catalytic subunit expressed in B cells, accelerates the 
development of lymphomas in transgenic mice 
overexpressing c-Myc in the B cells [50]. More generally, 
actions of AMPK that suggest it may be responsible for 
some of the tumor suppressor functions of LKB1 are as 
follows.
First, AMPK activation causes a cell cycle arrest 
associated with stabilization of p53 and the cyclin-
dependent kinase inhibitors p21WAF1 and p27CIP1 
[49,51,52]. Second, AMPK activation inhibits the 
synthesis of most cellular macromolecules, including 
fatty acids, triglycerides, cholesterol, glycogen, ribosomal 
RNA and proteins [53,54], thus inhibiting cell growth. It 
is particularly significant in this respect that AMPK 
inhibits the mechanistic target-of-rapamycin complex-1 
(mTORC1) by phosphorylating its upstream regulator 
TSC2 [55] and its regulatory subunit Raptor [56] and 
thus inhibits translation of many proteins required for 
rapid cell growth, including hypoxia-inducible factor-1α 
(HIF-1α). This latter effect contributes to the third 
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potential tumor suppressor action of the enzyme – the 
‘anti-Warburg’ effect. The Warburg effect is the switch 
away from oxidative metabolism and towards rapid 
glucose uptake, glycolysis and lactate output that is 
characteristic of most tumor cells [5]. Although AMPK 
activation can acutely increase glucose uptake [57] and 
glycolysis in certain cells [58,59], in the longer term it 
promotes the more energy-efficient oxidative 
metabolism, by up-regulating mitochondrial biogenesis 
[60] and expression of oxidative enzymes [61], while 
down-regulating the glycolytic pathway by inhibiting 
mTORC1. Inhibition of mTORC1 decreases translation 
of HIF-1α [62], a transcription factor that drives 
expression of enzymes and transporters required for the 
Warburg effect, including most glycolytic enzymes as 
well as the transporters GLUT1 and MCT4, which are 
required for glucose uptake and lactate output, 
respectively. Consistent with the idea that AMPK exerts 
an ‘anti-Warburg’ effect, expression of HIF-1α and 
downstream glycolytic genes are up-regulated in LKB1-
null or AMPK-α1 -α2 double null mouse embryo 
fibroblasts [63]. The Warburg effect is also enhanced in 
the lymphoma cells mentioned earlier, derived by c-Myc 
over-expression in B cells when AMPK was knocked out 
in vivo, as well as in lung and colon cancer cells in culture 
when AMPK is knocked down in vitro [50].
If the LKB1-AMPK pathway does indeed act as a tumor 
suppressor that normally restrains growth and 
proliferation of cancer cells as well as the associated 
metabolic changes, one would expect such cells to be 
under selective pressure to down-regulate the pathway. 
One obvious mechanism by which this happens is genetic 
loss of LKB1 due to somatic mutations which, as shown 
in our 2003 paper [1], leads to failure of AMPK activation 
following metabolic stresses that increase AMP and ADP 
(loss of LKB1 would, of course, down-regulate the ARKs 
as well as AMPK). Such mutations are now estimated to 
occur in approximately 30% of non-small cell lung 
cancers [64,65], approximately 20% of cervical cancers 
[66], and approximately 10% of cutaneous melanomas 
[67]. There are also other mechanisms by which the 
pathway can be down-regulated in cancer, through direct 
effects on AMPK rather than as downstream 
consequences of LBK1 inactivation. Thus, expression of 
the AMPK-α2 subunits is reduced in some cases of 
hepatocellular carcinoma, and this is associated with 
enhanced tumor cell growth in mouse xenografts, and 
poorer patient prognosis [68], while in melanoma cells 
that carry the V600E mutation in B-Raf, LKB1 appears to 
be phosphorylated at carboxy-terminal sites, and this is 
associated with reduced AMPK activation [69].
A further potential mechanism of AMPK down-
regulation that may contribute to tumorigenesis depends 
on an inhibitory effect of phosphorylation at Ser485 by 
Akt, which has been reported to prevent the activating 
phosphorylation at Thr172 [70]. This might occur in 
tumors in which Akt is hyper-activated due to loss-of-
function mutations in the lipid phosphatase PTEN, or 
activating mutations in phosphoinositide-3-kinase (PI3K) 
[71]. Although this mechanism has not yet been studied 
in the context of cancer, it has been shown to operate in 
human hepatoma cells infected with hepatitis C virus 
(HCV), in which Akt is activated due to interactions 
between PI3K and one of the virus-encoded non-
structural proteins, NS5A [72]. This causes a marked 
phosphorylation of Ser485 on AMPK-α1 and reduced 
Thr172 phosphorylation. Intriguingly, expression of an 
S485A AMPK-α1 mutant in the cells reduces expression 
of viral protein, suggesting that phosphorylation of 
AMPK at Ser485 is required for efficient viral replication 
[73]. Up to 80% of individuals infected with HCV develop 
a chronic infection, which greatly increases their risk of 
fatty liver disease and hepatocellular carcinoma [72]. 
Since activation of fatty acid oxidation and inhibition of 
fatty acid synthesis are two of the classical effects of 
AMPK [11], while AMPK can also act as a tumor 
suppressor, down-regulation of AMPK by HCV may help 
to explain the increased risk of both fatty liver disease 
and liver cancer.
AMPK, metformin, and the prevention or 
treatment of cancer
If the LKB1-AMPK pathway is indeed a tumor-
suppressing pathway, then AMPK-activating drugs might 
be expected to provide protection against the 
development of cancer. Indeed, our 2003 paper [1], taken 
together with the earlier observations that metformin 
activates AMPK [13], led directly to an investigation in 
which it was found that type 2 diabetics treated with the 
AMPK-activating drug metformin had a significantly 
reduced incidence of all forms of cancer [74]. This has 
been reproduced in several subsequent studies of 
different diabetic populations, with a meta-analysis 
indicating an overall summary risk reduction of 30%, 
with specific risk reductions being found for colon and 
liver cancers [75]. It should be noted that these studies 
merely report associations between cancer incidence in 
diabetics treated with metformin compared with those 
on other medications (typically sulphonylureas or 
insulin), and do not prove a causal link. They have also 
been criticized on the basis that they may be subject to 
time-related biases [76]. However, there are, as we have 
seen, other reasons for supposing that activation of 
AMPK may suppress tumorigenesis, and in this light 
there are at least three mechanisms that might explain its 
protective effects (Figure 5). The first mechanism 
(Figure 5a) involves the indirect action of metformin, 
through effects at sites other than the tumors themselves 
Hardie and Alessi BMC Biology 2013, 11:36
http://www.biomedcentral.com/1741-7007/11/36
Page 6 of 11
(especially the liver), while the other two (Figure 5b,c) 
involve direct effects of metformin on the pre-tumor or 
tumor cells. It is worth pointing out that these 
mechanisms are not mutually exclusive and all could 
contribute to an overall effect, although the second two 
mechanisms could not co-exist in a single tumor cell.
The first of the possible mechanisms (Figure 5a) derives 
from the observation that cancer incidence is increased 
in type 2 diabetics, and the contribution of AMPK in this 
case is not yet clear. In type 2 diabetes, reduced insulin 
sensitivity of insulin target tissues causes a compensatory 
increase in the secretion of insulin. Insulin is of course a 
growth factor, and there is a positive association between 
plasma levels of insulin and cancer [77], suggesting that 
elevated insulin (and perhaps also glucose) could be the 
cause of increased cancer in type 2 diabetics. In this case, 
metformin could reduce cancer incidence by enhancing 
the insulin sensitivity of insulin target tissues, causing 
normalization of blood glucose and reducing hyper-
secretion of insulin from pancreatic β cells. By contrast, 
other treatments, including sulphonylureas (which 
enhance insulin release from β cells), and injection of 
insulin, will tend to increase plasma insulin. Some 
support for this mechanism comes from studying growth 
of colon carcinoma (MC38) cells as mouse xenografts. 
When the mice are fed a high-fat diet to render them 
insulin-resistant and thus increase plasma insulin, 
growth of the implanted tumors is enhanced; metformin 
treatment reverses both the increase in plasma insulin 
and the tumor growth rate [78]. In such xenograft 
studies, the tumor cells of course already exist, and 
insulin is merely affecting their growth rate.
Direct effects of biguanides in tumor cells and the 
emergence of a paradox
Other studies suggest that metformin might delay the 
initial development of tumors by direct actions on the 
tumor cells themselves, even in animals that are not 
insulin-resistant. For example, in mice that are tumor-
prone due to heterozygous loss of PTEN combined with 
reduced expression of LKB1, development of tumors 
(mostly lymphomas) can be delayed by treating the mice 
from the time of weaning with metformin or phenformin, 
or by another AMPK activator, A769662 [79]. Since the 
Hardie and Alessi BMC Biology 2013, 11:36
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biguanides and A-769662 activate AMPK by different 
mechanisms [14], it is unlikely that the delay in 
tumorigenesis is due to off-target, AMPK-independent 
effects. In addition, neither class of drug activates any of 
the ARKs, making it unlikely that their protective effects 
have anything to do with other kinases downstream of 
LKB1. One possible mechanism for this effect (Figure 5b) 
is that activation of AMPK exerts a cytostatic effect on 
pre-neoplastic lesions through its ability to inhibit cell 
growth and progress through the cell cycle, and in this 
way delays the onset of tumorigenesis.
An alternative mechanism whereby biguanides could 
lead to the suppression of tumor growth derives from the 
inhibition by these drugs of the mitochondrial respiratory 
chain (Figure 5c) [14,80], although this action depends, 
paradoxically, not on the activation of the LKB1-AMPK 
pathway but on its down-regulation. Because cells with a 
defective LKB1-AMPK pathway are less able to restore 
ATP levels in response to metabolic stress [44,81,82], 
tumor cells in which the pathway has been down-
regulated may be less able to adapt to mitochondrial 
inhibition by biguanides, and thus more susceptible to 
cell death. There is some direct experimental support for 
this mechanism in the mouse xenograft study of MC38 
colon carcinoma cells mentioned earlier [78], in which 
treatment with metformin reduced the rate of tumor 
growth in insulin-resistant mice: growth of the xenografts 
was also slowed by metformin even when the mice were 
not insulin-resistant, but only if LKB1 had been first 
knocked down in the tumor cells using RNA interference. 
In another elegant study involving a mouse model of 
non-small cell lung cancer, phenformin prolonged 
survival of the mice when tumors were induced by 
activation of mutant K-Ras combined with loss of LKB1, 
but not when the mutant K-Ras was combined with loss 
of p53 [83]. Phenformin was used in this study because it 
is a more potent inhibitor of the respiratory chain than 
metformin [80], and appears to be less dependent on the 
expression of specific membrane transporters for its 
cellular uptake [14]. This again is consistent with the 
proposal that biguanides kill LKB1-deficient tumor cells 
because they are more sensitive to their ATP-depleting 
effects than the surrounding normal cells, which would 
still have a functional AMPK pathway. (Interestingly, cells 
classed as ‘cancer stem cells’ appear to be particularly 
sensitive to metformin, although the molecular 
mechanism underlying this is unclear [84,85].)
AMPK – tumor suppressor or tumor promoter?
Since our paper and the others [1-3] published nearly ten 
years ago suggested a link between AMPK and cancer, 
the once separate worlds of AMPK and metabolism, and 
mitogenic signaling in cancer cells have undergone a 
remarkable fusion. Considerable excitement has also 
been generated by the realization that inexpensive 
biguanide drugs with manageable side effects might have 
new applications in cancer. Pilot ‘window-of-opportunity’ 
trials of metformin in breast cancer have already been 
conducted [86,87], and much more ambitious prospective 
trials are planned.
However, it is also becoming apparent, as seen in the 
papers described above, that under different 
circumstances AMPK can be either a suppressor or a 
promoter of cancer. In the light of recent evidence, it 
seems possible that this may depend upon the stage in 
the development of the tumor. In pre-neoplastic lesions 
AMPK may act as a tumor suppressor, limiting cell 
growth and the switch from oxidative metabolism to the 
Warburg effect, and thus preventing conversion to full-
blown tumors: in this case, the pre-neoplastic cells will be 
under strong selective pressure to down-regulate the 
LKB1-AMPK pathway, explaining the observed 
inactivation of LKB1 in a significant proportion of 
tumors. Paradoxically, however, if a tumor becomes 
established without losing the function of the LKB1-
AMPK pathway, AMPK may help to keep the tumor cells 
alive by protecting them from metabolic stress. There is 
recent evidence in favor of the latter proposition. In a 
study of LKB1-deficient lung adenocarcinoma (A549) 
cells, it was found that re-expression of LKB1 protected 
the cells against cell death induced by glucose starvation, 
apparently through inhibition of fatty acid synthesis by 
AMPK and consequent sparing of NADPH, which could 
be utilized to provide protection against the oxidative 
stress induced by glucose deprivation [88]. In another 
study [89], both AMPK and the AMPK-related kinase 
NUAK1 (Ark5) were detected in a synthetic lethal RNA 
interference screen for kinases whose knock-down 
caused apoptosis of osteosarcoma (U2OS) cells over-
expressing c-Myc. This suggests that AMPK and NUAK1 
normally help to protect these cells against the stresses 
caused by the metabolic reprogramming that 
accompanies c-Myc over-expression.
Thus, the LKB1-AMPK pathway may act as a tumor 
suppressor through its ability to restrain the growth of 
pre-neoplastic lesions, but paradoxically may make 
established tumor cells more resistant to the metabolic 
stresses induced by biguanides or cytotoxic drugs, or that 
occurs when growth of the tumor outstrips the capacity 
of its blood supply to deliver oxygen and nutrients. It thus 
seems possible that the use of AMPK activators might be 
harmful in such cases, and there might be a need instead 
for specific inhibitors of AMPK.
This view is consistent with the recent study of a mouse 
model of non-small cell lung cancer already discussed 
above [83], which suggested that biguanides might be an 
effective method to treat tumors in which the function of 
the LKB1-AMPK pathway has been lost. In this situation, 
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biguanides are acting not as AMPK activators but as 
cytotoxic drugs that deplete cellular ATP. This study also 
suggested that phenformin might be more effective than 
metformin in this regard, because it is more cell-
permeable and a more potent inhibitor of the respiratory 
chain. Although phenformin was withdrawn for 
treatment of diabetes due to cases of lactic acidosis, this 
side effect was rare (<1 case per 1,000 patient-years) and 
might be more acceptable in treatment of cancer. Overall, 
a better understanding of the way in which the varied 
actions of AMPK interact with the different metabolic 
requirements of cancer cells is clearly essential to allow 
the more rational design of clinical trials of metformin 
and other AMPK-modulating drugs.
Future directions, both upstream of AMPK and 
downstream of LKB1
The other major findings that emerged in the immediate 
aftermath of our 2003 paper were that LKB1 also acted 
upstream of the AMPK-related kinases or ARKs, and that 
AMPK could also be activated by the Ca2+-CaMKK 
pathway. Although the functions of the ARKs have been 
slowly emerging since then, their regulation remains 
poorly understood. LKB1 appears to be constitutively 
active, and in the case of AMPK the regulation of Thr172 
phosphorylation is brought about by binding of ligands 
to AMPK, and not to LKB1. In the case of the ARKs, we 
do not understand how their phosphorylation by LKB1, 
and hence their activity, is regulated. Much also remains 
to be learned about the physiological role of AMPK 
activation by the Ca2+-CaMKK pathway. One intriguing 
question is whether inhibition of cell growth and 
proliferation by AMPK can be triggered by this pathway 
in tumor cells that have lost LKB1.
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